Xiangyang Central Hospital — Xiangyang, Hubei

Public research footprint of Xiangyang Central Hospital, compiled from the ClinicalTrials.gov public registry.

106

Registered studies

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Non-Small Cell Lung Cancer · Extensive-stage Small Cell Lung Cancer (ES-SCLC) · Carcinoma, Non-Small-Cell Lung · Breast Neoplasms

Recently updated registry entries

NCT06841354 — A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination… (Recruiting)
NCT07741448 — Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC (Recruiting)
NCT05388669 — A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Xiangyang Central Hospital?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 03, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.